On December 19, the Forum on the High-quality Development of China's Traditional Chinese Medicine Industry and the 2nd China Traditional Chinese Medicine Brand Building Conference hosted by the China Association of Traditional Chinese Medicine were held in Beijing. At the meeting, the 2020 "Clinical Value Chinese Patent Medicine Brand List" was released. Mengyang Pharmaceutical's flagship product, Shengbai Oral Liquid, stood out from the many traditional Chinese medicine varieties participating in the evaluation and was on the list by virtue of its high-level evidence-based evidence, outstanding drug clinical value, market value, scientific and technological value, quality assurance and brand influence. This is also the second time that Shengbai Oral Liquid has been on the list after 2019.

Mengyang Pharmaceutical Medical Insurance Exclusive Product Introduction

The "Clinical Value of Chinese Patent Medicine Brand List" focuses on the dominant diseases of traditional Chinese medicine, which is based on the research of the China Association of Traditional Chinese Medicine relying on the "Brand Value Enhancement of Traditional Chinese Medicine and Biopharmaceuticals" and the "Guidelines for the Clinical Application of Traditional Chinese Medicine in the Treatment of Dominant Diseases", according to the group standard of "Brand Evaluation of Traditional Chinese Medicine", in accordance with the evaluation system composed of core elements such as evidence-based evidence, clinical value, market value, scientific and technological value, quality assurance system and brand strength, and adheres to the principle of one-vote veto system on the negative list. The final selection will be made by the pharmacy and evidence-based expert review. Based on the above selection basis, evaluation criteria and system, as well as the selection process, the fairness, fairness, scientificity, objectivity and credibility of the list can be fully guaranteed.